Cannabinoid-1 receptor: A novel target for the treatment of neuropsychiatric disorders

Expert Opinion on Therapeutic Targets

Volumn 10, Issue 2, 2006, Pages 203-210

  Vinod, K Yaragudri ^a,b   Hungund, Basalingappa L ^a,b,c  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^b NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

^c NONE   (United States)

Author keywords

Alcoholism; Anxiety; Cannabinoid (CB1) receptor; Depression; Endocannabinoid; Schizophrenia

Indexed keywords

ANTIDEPRESSANT AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; ENDOCANNABINOID; FLUOXETINE; G PROTEIN COUPLED RECEPTOR; NEUROLEPTIC AGENT; RIMONABANT;

ALCOHOLISM; ANXIETY DISORDER; DEPRESSION; DRUG TARGETING; EMOTIONALITY; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; MENTAL DISEASE; MOOD; MOOD DISORDER; MOTIVATION; NERVE CELL NETWORK; NONHUMAN; PATHOPHYSIOLOGY; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; SUICIDAL BEHAVIOR;

DRUG DELIVERY SYSTEMS; ENDOCANNABINOIDS; HUMANS; MENTAL DISORDERS; RECEPTOR, CANNABINOID, CB1;

EID: 33645759691     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.10.2.203     Document Type: Review

References (91)

1. MUNRO S, THOMAS KL, ABU-SHAAR M: Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 365:61-65.
2. HERKENHAM M, LYNN AB, JOHNSON MR et al.: Characterization and localization of cannabinoid receptors in rat brain; a quantitative in vitro autoradiographic study. J. Neurosci. (1991) 11:563-583.
3. GLASS M, DRAGUNOW M, FAULL RLM: Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neurosci. (1997) 77:299-318.
4. BREIVOGEL CS, CHILDERS SR: The functional neuroanatomy of brain cannabinoid receptors. Neurobiol. Dis. (1998) 5:417-431.
5. DEVANE WA, HANUS L, BREUER A, PERTWEE RG, STEVENSON LA, GRIFFIN G: Isolation and structure of a brain constituent that binds to the CB receptor. Science (1992) 258:1946-1949.
6. MECHOULAM R, HANUS L, MARTIN BR: Search for endogenous ligands of the CB receptor. Biochem. Pharmacol. (1994) 48:1537-1544.
7. SUGIURA T, KONDO S, SUKAGAWA A, NAKANE S, SHINODA A, ITOH K et al.: 2-Arachidonoylglycerol: a possible endogenous CB receptor ligand in brain. Biochem. Biophy. Res. Comm. (1995) 215:89-97.
8. DI MARZO V, FONTANA A, CADAS H et al.: Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 372:686-691.
9. DEUTSCH DG, CHIN SA: Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. (1993) 46:791-796.
10. DEVANE WA, AXELROD J: Enzymatic synthesis of anandamide, an endogenous ligand for the cannabinoid receptor, by brain membranes. Proc. Natl. Acad. Sci. USA (1994) 91:6698-6701.
11. KRUSZKA KK, GROSS RW: The ATP- and CoA-independent synthesis of arachidonoylethanolamide. A novel mechanism underlying the synthesis of the endogenous ligand of the cannabinoid receptor. J. Biol. Chem. (1994) 269:14345-14358.
12. SUGIURA T, KONDO S, SUKAGAWA A et al.: K. Transacylase-mediated and phosphodiesterase-mediated synthesis of N-arachidonoylethanolamine, an endogenous cannabinoid-receptor ligand, in rat brain microsomes. Comparison with synthesis from free arachidonic acid and ethanolamine. Eur. J. Biochem. (1996) 240:53-62.
13. DI MARZO V, DE PETROCELLIS L, BISOGNO T, MELCK D: Metabolism of anandamide and 2-arachidonoylglycerol: an historical overview and some recent developments. Lipids (1999) 34:S319-S325.
14. HILLARD CJ, EDGEMOND WS, JARRAHIAN A, CAMPBELL WB: Accumulation of N-arachidonoylethanolamine (anandamide) into cerebellar granule cells occurs via facilitated diffusion. J. Neurochem. (1997) 69:631-638.
15. MACCARRONE M, VAN DER STELT M, ROSSI A, VELDINK GA, VLIEGENTHART JF, AGRO AF: Anandamide hydrolysis by human cells in culture and brain. J. Biol. Chem. (1998) 273:32332-32339.
16. BISOGNO T, MACCARRONE M, DE PETROCELLIS L et al.: The uptake by cells of 2-arachidonoylglycerol, an endogenous agonist of cannabinoid receptors. Eur. J. Biochem. (2001) 268:1982-1989.
17. DAY TA, RAKHSHAN F, DEUTSCH DG, BARKER EL: Role of fatty acid amide hydrolase in the transport of the endogenous cannabinoid anandamide. Mol. Pharmacol. (2001) 59:1369-1375.
18. DEUTSCH DG, GLASER ST, HOWELL JM et al.: The cellular uptake of anandamide is coupled to its breakdown by fatty-acid amide hydrolase. J Biol. Chem. (2001) 276:6967-6973.
19. HOWLETT AC: Pharmacology of cannabinoid receptors. Annu. Rev. Pharmacol. Toxicol. (1995) 35:607-634.
20. BREIVOGEL CS, SIM LJ, CHILDERS SR: Regional differences in cannabinoid receptor/G-protein coupling in rat brain. J. Pharmacol. Exp. Ther. (1997) 282:1632-1642.
21. MECHOULAM R, FRIDE E, DI MARZO V: Endocannabinoids. Eur. J. Pharmacol. (1998) 359:1-18.
22. SELF DW: Anandamide: a candidate neurotransmitter heads for the big leagues. Nat. Neurosci. (1999) 2:303-304.
23. WILSON RI, NICOLL RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588-592.
24. KREITZER AC, REGEHR WG: Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron (2001) 29:717-727.
25. 1) receptors. Psychopharmacol. (1997) 132:104-106.
26. COLOMBO G, AGABIO R, FA M et al.: Reduction of voluntary ethanol intake in ethanol-preferring sP rats by the CB antagonist SR-141716. Alcohol Alcoholism (1998) 33:126-130.
27. GALLATE JE, MCGREGOR IS: The motivation for beer in rats: effects of ritanserin, naloxone and SR 141716. Psychopharmacol. (1999) 142:302-308.
28. RODRIGUEZ DE FONSECA F, ROBERTS AJ, BILBAO A, KOOB GF, NAVARRO M: CB receptor antagonist SR141716A decreases operant ethanol self-administration in rats exposed to ethanol-vapor chambers. Zhongguo Yao Li Xue Bao (1999) 20:1109-1114.
29. 1 receptor knockout mice exhibit markedly reduced voluntary alcohol consumption and lack alcohol-induced dopamine release in the nucleus accumbens. J Neurochem. (2003) 84:698-704.
30. 1 receptor agonist. Eur. J Pharmacol. (1999) 370:233-240.
31. 1 receptor deleted mice. Neurosci. Lett. (2003) 343:216-218.
32. 1 receptor knockout mice. Neuropharmacol. (2004) 46:243-253.
33. 1 receptors. Behav. Brain Res. (2005) 164:206-213.
34. HUNGUND BL, VINOD KY: Modulation of cannabinoid-1 receptor-mediated G-protein signaling during ethanol tolerance and its withdrawal. Soc. Neurosci. (2004) 117.10.
35. ORTIZ S, OLIVA JM, PEREZ-RIAL S, PALOMO T, MANZANARES J: Chronic ethanol consumption regulates cannabinoid CB1 receptor gene expression in selected regions of rat brain. Alcohol Alcoholism (2004) 39:88-92.
36. 1 receptor binding and mRNA levels. Drug Alcohol Depend. (2002) 66:77-84.
37. BASAVARAJAPPA BS, HUNGUND BL: Chronic ethanol increases the CB receptor agonist anandamide and its precursor N-arachidonylphosphatidyl ethanolamine in SK-N-SH Cells. J. Neurochem. (1999) 72:522-528.
38. BASAVARAJAPPA BS, SAITO M, COOPER TB, HUNGUND BL: Chronic ethanol inhibits the anandamide transport and increases extracellular anandamide levels in cerebellar granule neurons. Eur J. Pharmacol. (2003) 466:73-83.
39. 1 receptor function in selective brain areas and vulnerability to voluntary alcohol consumption in Fawn Hooded and Wistar rats. Alcohol Alcoholism (2004) 39:297-302.
40. BLAZER DG: Mood disorders: epidemiology. In: Sadock BJ and Sadock VA (Eds), Comprehensive Textbook of Psychiatry, Lippincott, Williams & Wilkins, New York, USA (2000):1298-1308.
41. FRAZER A: Pharmacology of antidepressants. J. Clin. Psychopharmacol. (1997) 1:2S-18S.
42. 1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions. Br. J. Pharmacol. (2003) 138:544-553.
43. HILL MN, SUN JC, TSE MT, GORZALKA BB: Altered responsiveness of serotonin receptor subtypes following long-term cannabinoid treatment. Int. J. Neuropsychopharmacol. (2005) 21:1-10.
44. 1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol. Psychiat. (2005) 57:261-267.
45. 1 receptor inverse agonist AM251 in mice. Behav. Pharmacol. (2003) 14:573-582.
46. 35S]GTPγS binding in the prefrontal cortex of depressed suicide victims. Mol. Psychiat. (2004) 9:184-190.
47. OLIVA JM, URIGUEN L, PEREZ-RIAL S, MANZANARES J: Time course of opioid and cannabinoid gene transcription alterations induced by repeated administration with fluoxetine in rat brain. Neuropharmacol. (2005) 49:618-626.
48. HILL MN, PATEL S, CARRIER EJ et al.: Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacol. (2005) 30:508-515.
49. BILKEI-GORZO A, RACZ I, VALVERDE O et al.: Early age-related cognitive impairment in mice lacking cannabinoid CB1 receptors. Proc. Natl. Acad. Sci. USA (2005) 102:15670-15675.
50. ASHTON CH, MOORE PB, GALLAGHER P, YOUNG AH: Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. J. Psychopharmacol. (2005) 19:293-300.
51. GOBBI G, BAMBICO FR, MANGIERI R et al.: Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc. Natl. Acad. Sci. USA (2005) 102:18620-18625.
52. 1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biol. Psychiat. (2005) 83:480-486.
53. RODRIGUEZ DE FONSECA F, RUBIO P, MENZAGHI F et al.: Corticotropin-releasing factor (CRF) antagonist [D-Phe12,Nle21,38,C alpha MeLeu37]CRF attenuates the acute actions of the highly potent cannabinoid receptor agonist HU-210 on defensive-withdrawal behavior in rats. J. Pharmacol. Exp. Ther. (1996) 276:56-64.
54. HILL MN, GORZALKA BB: Enhancement of anxiety-like responsiveness to the cannabinoid CB(1) receptor agonist HU-210 following chronic stress. Eur. J. Pharmacol. (2004) 499:291-295.
55. ZUARDI AW, SHIRAKAWA I, FINKELFARB E, KARNIOL IG: Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacol. (Berl). (1982) 76:245-250.
56. 1 cannabinoid receptor antagonist SR 141716A induces anxiety-like responses in the rat. Neuroreport (1997) 8:491-496.
57. KATHURIA S, GAETANI S, FEGLEY D et al.: Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med. (2003) 9:76-81.
58. AKINSHOLA BE, CHAKRABARTI A, ONAIVI ES: In-vitro and in-vivo action of cannabinoids. Neurochem. Res. (1999) 24:1233-1240.
59. 1 cannabinoid receptor on anxiety. Eur. J Neurosci (2002) 16:1395-1398.
60. RODGERS RJ, HALLER J, HALASZ J, MIKICS E: 'One-trial sensitization' to the anxiolytic-like effects of cannabinoid receptor antagonist SR141716A in the mouse elevated plus-maze. Eur. J. Neurosci. (2003) 17:1279-1286.
61. MARSICANO G, WOTJAK CT, AZAD SC et al.: The endogenous cannabinoid system controls extinction of aversive memories. Nature (2002) 418:530-534.
62. 1 receptors improves non-associative learning. Behav. Brain Res. (2005) 162:161-164.
63. CHHATWAL JP, DAVIS M, MAGUSCHAK KA, RESSLER KJ: Enhancing cannabinoid neurotransmission augments the extinction of conditioned fear. Neuropsychopharmacol. (2005) 30:516-524.
64. 1 cannabinoid receptor knockout mice: correlation with behaviour. Eur. J. Neurosci. (2002) 15:1178-1186.
65. MARTIN M, LEDENT C, PARMENTIER M, MALDONADO R, VALVERDE O: Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacol. (2002) 159:379-387.
66. WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
67. 2 receptors. Science (2005) 310:329-332.
68. WOTJAK CT: Role of endogenous cannabinoids in cognition and emotionality. Mini Rev. Med. Chem. (2005) 5:659-670.
69. WEIDENFEL J, FELDMAN S, MECHOULAM R: Effect of the brain constituent anandamide, a cannabinoid receptor agonist, on the hypothalamo-pituitary-adrenal axis in the rat. Neuroendocrinol. (1994) 59:110-112.
70. DI MARZO V, MELCK D, BISOGNO T, DE PETROCELLIS L: Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci. (1998) 21:521-518.
71. MANZANARES J, CORCHERO J, FUENTES JA: Opioid and cannabinoid receptor-mediated regulation of the increase in adrenocorticotropin hormone and corticosterone plasma concentrations induced by central administration of delta(9)-tetrahydrocannabinol in rats. Brain Res. (1999) 839:173-179.
72. MURPHY LL, MUNOZ RM, ADRIAN BA, VILLANUA MA: Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol. Dis. (1998) 5:432-446.
73. SAWA A, SNYDER SH: Schizophrenia: diverse approaches to a complex disease. Science (2002) 296:692-695.
74. HALL W, DEGENHARDT L, TEESSON M: Cannabis use and psychotic disorders: an update. Drug Alcohol Rev. (2004) 23:433-443.
75. GREEN AI: Schizophrenia and comorbid substance use disorder: effects of antipsychotics. J. Clin. Psychiatry (2005) 66:21-26.
76. SEMPLE DM, MCINTOSH AM, LAWRIE SM: Cannabis as a risk factor for psychosis: systematic review. J. Psychopharmacol. (2005) 19:187-194.
77. KORNHUBER J, WILTFANG J, BLEICH S: The etiopathogenesis of schizophrenias. Pharmacopsychiatry (2004) 37:103-112.
78. EMRICH HM, LEWEKE FM, SCHNEIDER U: Towards a CB hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous CB system. Pharmacol. Biochem. Beh. (1997) 56:803-807.
79. UJIKE H, TAKAKI M, NAKATA K et al.: CNR1, central cannabinoid receptor gene, associated with susceptibility to hebephrenic schizophrenia. Mol. Psychiat. (2002) 7:515-518.
80. 3H]CP-55940 binding in the human central nervous system: regional specific changes in density of CB-1 receptors associated with schizophrenia and cannabis use. Neurosci. (2001) 103:9-15.
81. 1 receptors is increased in the anterior cingulate cortex in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiat. (2004) 28:355-360.
82. BUSH G, LUU P, POSNER MI: Cognitive and emotional influences in anterior cingulate cortex. Tends Cogn. Sci. (2000) 4:215-222.
83. SIM-SELLEY LJ, VOGT LJ, VOGT BA, CHILDERS SR: Cellular localization of cannabinoid receptors and activated G-proteins in rat anterior cingulate cortex. Life Sci. (2002) 71:2217-2226.
84. LEWEKE FM, GIUFFRIDA A, WURSTER U, EMRICH HM, PIOMELLI D: Elevated endogenous cannabinoids in schizophrenia. Neuroreport (1999) 10:1665-1667.
85. DE MARCHI N, DE PETROCELLIS L, ORLANDO P, DANIELE F, FEZZA F, DI MARZO V: Endocannabinoid signaling in the blood of patients with schizophrenia. Lipids Health Dis. (2003) 2:2-5.
86. GIUFFRIDA A, LEWEKE FM, GERTH CW et al.: Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacol. (2004) 29:2108-2114.
87. HERKENHAM M, LYNN AB, DE COSTA BR, RICHFIELD EK: Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Res. (1991) 547:267-274.
88. HERMANN H, MARSICANO G, LUTZ B: Coexpression of the cannabinoid receptor Type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neurosci. (2002) 109:451-460.
89. 1 receptor. J. Neurosci. (1997) 17:5327-5333.
90. VORUGANTI LN, SLOMKA P, ZABEL P, MATTAR A, AWAD AG: Cannabis induced dopamine release: an in-vivo SPECT study. Psychiat. Res. (2001) 107:173-177.
91. GIUFFRIDA A, PARSONS LH, KERR TM et al.: Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat. Neurosci. (1999) 2:358-363.